0001193125-07-232121 Sample Contracts

MYRIAD GENETICS, INC. INCENTIVE STOCK OPTION AGREEMENT
Incentive Stock Option Agreement • November 1st, 2007 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware

This Agreement sets forth the terms of the incentive stock option (“ISO”) grant made by Myriad Genetics, Inc. (the “Company”), a Delaware corporation having a principal place of business in Salt Lake City, Utah, to the individual specified in the Notice of Grant of Stock Option and Option Agreement (the “Employee”).

LICENSE AND COLLABORATION AGREEMENT
License and Collaboration Agreement • November 1st, 2007 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware

THIS LICENSE AND COLLABORATION AGREEMENT (the “Agreement”) is entered into as of November 19, 2003 (the “Effective Date”) by and among MAXIM PHARMACEUTICALS, INC., a Delaware corporation (“Maxim Pharmaceuticals”), having an address of 8899 University Center Lane, Suite 400, San Diego, California 92122, and CYTOVIA, INC., a Delaware corporation and wholly-owned subsidiary of Maxim Pharmaceuticals (“Cytovia”), having an address of 8899 University Center Lane, Suite 400, San Diego, California 92122 (Maxim Pharmaceuticals and Cytovia are hereinafter collectively referred to as “Maxim”), and MYRIAD GENETICS, INC., a Delaware corporation, having an address of 320 Wakara Way, Salt Lake City, Utah 84108 (“Myriad”).

MYRIAD GENETICS, INC. INCENTIVE STOCK OPTION AGREEMENT
Incentive Stock Option Agreement • November 1st, 2007 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware

This Agreement sets forth the terms of the incentive stock option (“ISO”) grant made by Myriad Genetics, Inc. (the “Company”), a Delaware corporation having a principal place of business in Salt Lake City, Utah, to the individual specified in the Notice of Grant of Stock Option and Option Agreement of the Company (the “Employee”).

EXCLUSIVE LICENSE AGREEMENT
Exclusive License Agreement • November 1st, 2007 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Utah

This EXCLUSIVE LICENSE AGREEMENT is made and is effective this 15th day of March, 1995, by and between the Hospital for Sick Children, having a principal place of business in Toronto, Canada, hereinafter referred to as “LICENSOR”, and MYRIAD GENETICS, INC., having a principal place of business at 390 Wakara Way, Salt Lake City, Utah 84108, hereinafter referred to as “LICENSEE”.

MYRIAD GENETICS, INC. NON-QUALIFIED OPTION AGREEMENT
Non-Qualified Option Agreement • November 1st, 2007 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware

This Agreement sets forth the terms of the nonqualified stock option (“NQSO”) grant made by Myriad Genetics, Inc. (the “Company”), a Delaware corporation having a principal place of business in Salt Lake City, Utah, to the individual specified in the Notice of Grant of Stock Option and Option Agreement (the “Participant”).

EXCLUSIVE LICENSE AGREEMENT BETWEEN MYRIAD GENETICS, INC. AND THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s...
Exclusive License Agreement • November 1st, 2007 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Pennsylvania

This Exclusive License Agreement (“AGREEMENT”) is made by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at 3700 Market Street, Suite 300, Philadelphia, Pennsylvania 19104-3147 (“PENN”) and Myriad Genetics, Inc., a corporation organized and existing under the laws of Delaware (“MYRIAD”), having a place of business at 390 Wakara Way, Salt Lake City, UT 84108.

MYRIAD GENETICS, INC. NON-QUALIFIED STOCK OPTION AGREEMENT
Non-Qualified Stock Option Agreement • November 1st, 2007 • Myriad Genetics Inc • In vitro & in vivo diagnostic substances • Delaware

This Agreement sets forth the terms of the Non-Qualified Option grant made by Myriad Genetics, Inc. (the “Company”), a Delaware corporation having a principal place of business in Salt Lake City, Utah, to the individual specified in the Notice of Grant of Stock Option and Option Agreement (the “Participant”).